THERAPY DOSSIER · th-866511d1214e

Bone marrow-derived mesenchymal stem cells; mesenchymal stem cell secretome

Biologic · Cell therapy (bone-marrow MSCs and MSC secretome); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Cell therapy (bone-marrow MSCs and MSC secretome); not a ChEMBL entity
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06629909 ↗PHASE1not yet recruiting

Human Umbilical Cord MSC-Derived Secretome in Liver Cirrhosis

Liver Cirrhosis

Enrolment: 54 · Results not recorded

NCT07137130 ↗NAnot yet recruiting

Adipose-Derived MSC Secretome Products From Conditioned Medium for Melasma

Melasma

Enrolment: 34 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22106021 ↗2011Reported benefit

Mesenchymal stem cells enhance recovery and repair following ventilator-induced lung injury in the rat.

RatOtherSprague-DawleyMaleIntravenous injection2 x 10^6 cells per doseFirst dose immediately after recovery from injurious ventilation, second dose 2…

Model: Ventilator-induced lung injury produced by injurious mechanical ventilation in anaesthetised rats followed by recovery

Mesenchymal stem cell therapy enhanced repair after ventilator-induced lung injury, restoring oxygenation and compliance, reducing total lung water, inflammation and histological injury, lowering alveolar TNF-alpha and raising interleukin-10. Rat fibroblasts had no such effect. The cell-free secret…

Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.

Loading the evidence…